Description
EACH LUCICRIZ CAPSULE CONTAINS:
Crizotinib 250mg
INDICATION:
LuciCriz is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test.
DOSAGE AND USE:
The recommended dosage is 250 mg orally twice daily.
Capsules should be swallowed whole & not chewed or crushed.
STORAGE:
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).
Keep medicine out of the reach of Children.
MANUFACTURED AND MARKETED BY:
LUCIUS PHARMACEUTICALS(LAO) CO., LTD
No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING AND PRECAUTION:
To be sold by retail on prescription of a Registered oncologist only, and as directed by the physician.
Reviews
There are no reviews yet.